Drug Induced Liver Injury (DILI): a short review

Letter of support for drug-induced liver injury (DILI) biomarker

The objectives of DILI WP3 were to qualify one or a set of new biomarkers with respect to: an early or earlier diagnosis of DILI as compared to current diagnostic rules the ability to predict DILI outcome, with particular emphasis on severe DILI/acute liver failure the prognosis and monitoring of progression and regression of DILI the differentiation between patients who incur true drug-induced...

drug induced liver injury: a review article

the incidence of drug induced liver injury (dili) is about 1/1000 to 1/10000 among patients who receive therapeutic drug doses. drug induced hepatotoxicity is a major cause of acute and chronic liver disease. the severity of liver damage ranges from nonspecific changes in liver structure to acute liver failure, cirrhosis and liver cancer. some common agents that can cause liver injury are aceta...

Idiosyncratic drug‐induced liver injury: A short review

Idiosyncratic drug-induced liver injury (iDILI) is a rare adverse drug reaction that occasionally leads to acute liver failure or even death. An aging population that uses more drugs, a constant influx of newly developed drugs, and a growing risk from herbal and dietary supplements of uncertain quality can lead to an increase in iDILI. Antimicrobials, central nervous system agents, and herbal a...

The Challenge of Drug-Induced Liver Injury (DILI) / Challenges and Management of Liver Cirrhosis. Preface.

The rediscovery of HepG2 cells for prediction of drug induced liver injury (DILI)

In the past HepG2 cells have been considered to show only little similarity to primary human hepatocytes (Godoy et al., 2013; Hewitt et al., 2007). However, recently it has become clear that the phenotype of HepG2 cells strongly depends on culture conditions. In a recent study, Ramaiahgari et al. (2014) cultivated HepG2 cells in spheroids. In this culture system the cells stopped proliferation ...